Literature DB >> 8683594

Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics.

J Rogers1, A H Chang, U von Ahsen, R Schroeder, J Davies.   

Abstract

Human hepatitis delta virus (HDV) poses a health threat in populations where chronic hepatitis B is endemic. It is a single-stranded RNA virus of 1700 nucleotides and both genomic and antigenomic sequences contain ribozymes which are important for viral replication. Using ribozyme constructs we show that several classes of antibiotics inhibit the self-cleavage reaction of the HDV ribozyme. Antibiotics of the aminoglycoside, peptide and tetracycline classes all inhibit HDV cleavage in vitro at micromolar concentrations. Neomycin (an aminoglycoside) inhibits HDV self-cleavage with a Ki value of 28 (+/- 10) microM. Neomycin inhibition can be reversed by increasing magnesium ion concentration in a competitive manner. Lead acetate cleaves positions G76, A42 and G28, which surround the ribozyme cleavage site. Both Mg2+ and neomycin prevent lead cleavage. Footprinting experiments using base-specific chemical probes revealed enhanced modifications of a set of bases by neomycin, overlapping with the above mentioned lead cleavages. These observations may indicate that neomycin directly displaces divalent metal ions essential for catalysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683594     DOI: 10.1006/jmbi.1996.0369

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  26 in total

1.  Presence of a coordinated metal ion in a trans-acting antigenomic delta ribozyme.

Authors:  D A Lafontaine; S Ananvoranich; J P Perreault
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

Review 2.  Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance.

Authors:  L P Kotra; J Haddad; S Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Kinetic and binding analysis of the catalytic involvement of ribose moieties of a trans-acting delta ribozyme.

Authors:  Karine Fiola; Jean-Pierre Perreault
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

4.  Inhibition of RNase P RNA cleavage by aminoglycosides.

Authors:  N E Mikkelsen; M Brännvall; A Virtanen; L A Kirsebom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Inhibition of protein synthesis by aminoglycoside-arginine conjugates.

Authors:  Marjolaine Carriere; Veerappan Vijayabaskar; Drew Applefield; Isabelle Harvey; Philippe Garneau; Jon Lorsch; Aviva Lapidot; Jerry Pelletier
Journal:  RNA       Date:  2002-10       Impact factor: 4.942

6.  Effect of peptidyltransferase inhibitors on ribonuclease P activity from Dictyostelium discoideum. Effect of antibiotics on RNase P.

Authors:  C Stathopoulos; A Tsagla; A Tekos; D Drainas
Journal:  Mol Biol Rep       Date:  2000-06       Impact factor: 2.316

7.  Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.

Authors:  Lucien Junior Bergeron; Jonathan Ouellet; Jean-Pierre Perreault
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

8.  In vitro selection of ribozymes dependent on peptides for activity.

Authors:  Michael P Robertson; Scott M Knudsen; Andrew D Ellington
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

9.  Complete thermodynamic characterization of the multiple protonation equilibria of the aminoglycoside antibiotic paromomycin: a calorimetric and natural abundance 15N NMR study.

Authors:  Christopher M Barbieri; Daniel S Pilch
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

10.  Detailed analysis of base preferences at the cleavage site of a trans-acting HDV ribozyme: a mutation that changes cleavage site specificity.

Authors:  F Nishikawa; H Fauzi; S Nishikawa
Journal:  Nucleic Acids Res       Date:  1997-04-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.